ArticleJournal of cellular and molecular medicine2025
Comparative Analysis of miRNA Expression 106a-5p and 375-3p and Proteins ERK1/2, p38, β-Catenin and E-Cadherin in Prostate Cancer and Benign Prostatic Hyperplasia.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Analysis of miRNA Expression 106a-5p and 375-3p and Proteins ERK1/2, p38, β-Catenin and E-Cadherin in Prostate Cancer and Benign Prostatic Hyperplasia.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer is the most frequently diagnosed cancer in men and the second most common cause of death. PSA is performed in men to detect prostate cancer early, but PSA levels increase in both cancer and BPH. Therefore, there is an important need to understand prostate-specific molecular signatures. Considering the importance of the MAPK and Wnt/β-catenin pathways in the progression of many cancers and the fact that the miRNA expression profile is unique in each cancer type, evaluation of 106a-5p and 375-3p miRNAs may be an important factor in cancer detection. The research was carried out on tissue fragments taken from 30 patients with BPH and 30 with cancer. IHC and qRT-PCR were used to identify the expression of tested proteins, while the expression of miRNAs was examined using dPCR. The results of the present study showed significantly higher fluorescence intensity of miRNAs 106a-5p and 375-3p, and lower immunoreactivity and the expression of genes encoding ERK1/2, p38, β-catenin and E-cadherin in prostate cancer compared to BPH. It is possible that thanks to miRNA 106a-5p and 375-3p, the proteins we studied belonging to the MAPK and Wnt/β-catenin pathways play a protective suppressor role in prostate cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.